Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Odyssey Group Intl Inc (OP: ODYY )

0.0325 -0.0075 (-18.75%)
Streaming Delayed Price Updated: 3:39 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 59,000
Open 0.0325
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0400
Today's Range 0.0325 - 0.0350
52wk Range 0.0210 - 0.2350
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc.
Via ACCESSWIRE
Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.
Via ACCESSWIRE

Performance

YTD
-70.45%
-70.45%
1 Month
-34.87%
-34.87%
3 Month
-54.86%
-54.86%
6 Month
-70.45%
-70.45%
1 Year
-56.90%
-56.90%

More News

Read More
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion
Via ACCESSWIRE
Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders
Via ACCESSWIRE
Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.
Via ACCESSWIRE
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
From Oragenics, Inc.
Via Business Wire
Odyssey Health Inc. Begins Trading on the OTCQB
Via ACCESSWIRE
Odyssey Health, Inc. Presents Concussion Treatment Data at the Military Health System Research Symposium - MHSRS
Via ACCESSWIRE
Odyssey Health, Inc. Presents Data at the Special Operations Medical Association - Scientific Assembly
Via ACCESSWIRE
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment
Via TheNewswire.com
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment
Via News Direct
Odyssey Health, Inc. Forms Community-Based Partnership with David R. Metcalf Foundation for Military Concussion Research
Via News Direct
Topics Death
Exposures Death
Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023
Via Investor Brand Network
Topics Animal Testing
Exposures Animal Testing
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
World Cup 2022 to Feature New Protocol to Respond to Suspected Concussions
Via Investor Brand Network
Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies
Via Investor Brand Network
Surgical Team in Spain Completes First-Ever Intestinal Transplant
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Upcoming Annual Meeting of Stockholders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Study Finds Iron Causes Chronic Heart Failure in Heart Attack Survivors
Via Investor Brand Network
New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments
Via Investor Brand Network
Experts Concerned That Concussion Protocols Don’t Factor in Women
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Expansion of Executive Team
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Files for Patent Protection on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Pleased with Safety Profile of Its PRV-002 Concussion Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.